Navigation Links
Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
Date:11/5/2013

SAN DIEGO, Nov. 5, 2013 /PRNewswire/ -- Pfenex Inc. today announced that it has awarded Paragon Bioservices a contract for the current Good Manufacturing Practice (cGMP) manufacturing of its rPA based anthrax vaccine. Paragon Bioservices will implement the cGMP-ready Pfenex Expression Technology™-based production process that has been developed at Pfenex, through its vaccines division.  Funding will be provided by the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA).

"We are pleased to award this contract to Paragon Bioservices," stated Bertrand C. Liang, Chief Executive Officer. "This is the next step in reaching our common objective with BARDA to develop an anthrax vaccine with a product capable of achieving the goals of the Strategic National Stockpile for the U. S. Government, including cost, shelf life, and administration improvements. With Paragon Bioservices we believe we will rapidly implement the large-scale cGMP production of the rPA required for our Phase 1 clinical trial."

Marco A. Chacon, Ph.D., CEO of Paragon stated, "My team and I are dedicated to providing manufacturing support to Pfenex, using their powerful protein expression technology. This project becomes all the more important since it will enrich the national armamentarium of vaccines against potential bio weapons."

About Pfenex Inc.

Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs. Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division. For more information please visit www.pfenex.com  

About Paragon Bioservices Inc.

Founded in 1990, Paragon Bioservices is a contract research and manufacturing organization whose focus is the production of reagent-grade proteins and biopharmaceuticals for clinical use. Areas of expertise include: Vaccines, VLP technologies, therapeutic proteins, monoclonal antibodies and viral vectors. The cGMP manufacturing space includes microbial and mammalian suites, fill-finish, and fully-segregated Virus/BSL-3 facilities.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
2. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
3. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
4. Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
7. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
8. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
9. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
10. Trinity College Dublins Neuroscience and Bioengineering Programmes Receive Postgraduate Course of the Year Awards
11. aTyr Pharma Receives Industry Innovation Awards from TiE and San Diego Venture Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , ... February 17, 2017 , ... ... Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research ... in Orlando, Fla. , The combined scientific sessions offer investigators, clinicians, ...
(Date:2/17/2017)... Feb. 17, 2017  BioGenex, a global leader ... of a novel system for quantitative immunohistochemistry (IHC). ... University of Rochester (NY, USA) and Konica-Minolta Inc. ... system is able to accurately quantify the expression ... epidermal growth factor receptor-2) in clinical samples. Quantitative ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart ... about to get under way for the framework, which is designed to reduce the ... expected to be transferred eventually to other industries that also require efficient IoT and ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):